Albany, NY -- (SBWIRE) -- 12/31/2018 -- ResearchMoz.us has announced the addition of a report, titled "Osteoarthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026". The report on the global osteoarthritis drugs market is an in-depth study on the current outlook of the market, key demand dynamics, investment strategies by various players, and lucrative growth avenues. The study also offers insights into the promising drug classes and takes a closer look at recent clinical developments.
The global osteoarthritis drugs market is projected to expand at promising, single-digit CAGR from 2018 to 2026. The marked prevalence of degenerative bone diseases, especially in emerging economies, and that of symptomatic knee osteoarthritis is a key factor driving the demand for osteoarthritis drugs.
A rapidly rising geriatric population, especially in developing and developed countries, has accentuated the incidence rate of common joint disorders. This has bolstered the need for better treatments, thus catalyzing the global osteoarthritis drugs market's growth. Furthermore, the worldwide epidemic of obesity is a co-morbid factor, upping the risk of joint disorders and osteoarthritis.
Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1950991
World over, there have been relentless research activities in developing drugs that modify the diseases and help in its better management. Sizeable investments have been made by key players on clinical studies for building on their osteoarthritis drugs pipelines. The growing awareness about degenerative bone diseases in developing countries points to large unmet needs, which may create substantial revenue streams to drug makers in the market.
The various drug classes are viscosupplementation agents, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs). Of these, the viscosupplementation agents segment are expected to contribute the major revenue share in the global osteoarthritis drugs market. The demand for these drugs is likely to rise at substantial rate over the assessment period. This is attributed to the rising effectiveness of these in the treatment of knee osteoarthritis and in managing the chronic pain.
The substantial risk of impaired mobility associated with osteoarthritis has bolstered the need for drugs that can cure the condition. The demand for novel osteoarthritis drugs is expected to open new, exciting avenues in the market. However, since viscosupplementation entails high cost and also faces stiff competition from generic drugs, the prospects of the market is seriously hampered. Moreover, the rising trend of opioid use has also adversely impacted the market's growth.
Nevertheless, rising number of launches of efficacious drugs in developed countries and rapid progress being made in healthcare facilities in developing countries are notable factors boosting the osteoarthritis drugs market's revenue. The advent of NGF-sequestering antibodies for pain management is a promising development expected to boost the drug pipeline of key players of the market.
Prominent players operating in the osteoarthritis drugs market include Zimmer Biomet, Flexion Therapeutics, Inc., Chugai Pharmaceutical Co., Limited, Ferring B.V., Sanofi, and Horizon Pharma plc.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG